8. Inventories
|
|
At December 31, |
||||
(in thousands of $) |
|
2022 |
|
2021 |
|
2020 |
Raw materials and consumables |
|
126,046 |
|
70,134 |
|
18,608 |
Inventories in process |
|
65,016 |
|
37,705 |
|
6,587 |
Finished goods |
|
37,291 |
|
1,237 |
|
– |
Total inventories |
|
228,353 |
|
109,076 |
|
25,195 |
The cost of inventories, which is recognized as an expense and included in the “cost of sales” on the consolidated statements of profit or loss, amounted to $29.4 million for the year ended December 31, 2022.
On December 31, 2022, inventories amounted to $99.3 million was related to pre-launch SC efgartigimod inventory. Of the total inventory, $76.5 million relates to inventory which is currently awaiting facility approval. As of December 31, 2022, no inventory write-downs were recorded.
Included in inventory are products which could, besides commercial activities, be used for in-house preclinical and clinical programs, non-reimbursed pre-approval programs and clinical programs carried out by Zai Lab.